Byron J. Hoogwerf

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

Faramarz Ismail‐Beigi, Timothy E. Craven, Mary Ann Banerji et al. · The Lancet · 2010 · 1.4K citations · Full text

Metabolic Syndrome, Diabetes Management, Health Policy +11

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först et al. · The Lancet · 2012 · 559 citations

Diabetes Management, Diabetes, Type 2 +5

Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Rodica Pop‐Busui, Gregory W. Evans, Hertzel C. Gerstein et al. · Diabetes Care · 2010 · 526 citations · Full text

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

John B. Buse, Richard M. Bergenstal, Leonard C. Glass et al. · Annals of Internal Medicine · 2011 · 503 citations

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Bernard Zinman, Byron J. Hoogwerf, Santiago Durán García et al. · Annals of Internal Medicine · 2007 · 428 citations